Chemotherapy-induced Peripheral Neuropathy Clinical Trial
Official title:
A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy
This study will assess pharmacokinetic (PK)/pharmacodynamic (PD) relationships and whether BXQ-350 may decrease the intensity and/or duration of chemotherapy induced peripheral neuropathy (CIPN) thereby improving quality of life (QoL) in cancer patients who have been exposed to oxaliplatin and/or taxane-based chemotherapy. This study includes two randomized, placebo controlled, blinded treatment cycles of BXQ-350/placebo, an optional open-label BXQ-350 treatment period, and an unblinded Post-Treatment Follow-up period.
BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a cell membrane phospholipid (clinical formulation BXQ-350).Due to the presumed mechanism of action of BXQ-350, Bexion anticipates that it may have an impact on ceramides, sphingosine-1-phosphate (S1P), and inflammatory cytokine levels. In addition, pre-clinical results demonstrated that BXQ-350 induced neurite generation and protection in vitro in the PC-12 and NS20Y cell lines and significantly decreased oxaliplatin-induced cold allodynia in a model of CIPN. Thus BXQ-350 may represent a new approach to deliver a neuropathy benefit. The unique combination of SapC-DOPS along with its proven safety profile and possible neuropathy benefit makes BXQ-350 a worthwhile candidate to test on cancer patients affected by CIPN. The aim of this pilot proof-of-concept study is to assess PK/PD relationships in cancer patients with CIPN symptoms in order to determine the impact BXQ-350 has on ceramide, S1P, and inflammatory cytokine levels; thereby potentially reducing the intensity and/or duration of CIPN, improving QoL, and establishing these signaling molecules as biomarkers in future studies. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.) ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05528263 -
Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
|
N/A | |
| Completed |
NCT03272919 -
Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Not yet recruiting |
NCT06430814 -
Clinical Biomarker of Paclitaxel-induced Peripheral Neuropathy
|
||
| Not yet recruiting |
NCT05840562 -
Capsaicin 179 mg Patch Versus Oral Duloxetine in Patients With Chemotherapy-induced Peripheral Neuropathy
|
Phase 3 | |
| Completed |
NCT02553863 -
The Effectiveness and Cost-effectiveness of Acupuncture in Managing Chemotherapy-induced Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT04786977 -
Physiologic Measure of VIPN
|
||
| Completed |
NCT03655587 -
Impact of an Orthotic Intervention in Children With Peripheral Neuropathy
|
N/A | |
| Completed |
NCT03687970 -
A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)
|
N/A | |
| Terminated |
NCT04770402 -
Acupuncture for Chemo-Induced Peripheral Neuropathy in Multiple Myeloma Patients
|
N/A | |
| Completed |
NCT03254394 -
Lidocaine for Oxaliplatin-induced Neuropathy
|
Phase 1/Phase 2 | |
| Completed |
NCT04367480 -
Effects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral Neuropathy
|
N/A | |
| Recruiting |
NCT04237194 -
A New Diagnostic Method to Assess Paclitaxel-Induced Peripheral Neuropathy
|
||
| Completed |
NCT04843410 -
Effect of Exercise in the Management of Peripheral Neuropathy
|
N/A | |
| Terminated |
NCT03782402 -
Cannabinoids for Taxane Induced Peripheral Neuropathy
|
Phase 2 | |
| Not yet recruiting |
NCT06389721 -
Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
|
||
| Recruiting |
NCT05121558 -
The Effect of Yoga on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
|
Phase 3 | |
| Withdrawn |
NCT04492436 -
A Trial Measuring ART-123 Ability to Prevent Sensory Neuropathy in Unresectable mCRC Subjects w/Oxaliplatin-based Chemo
|
Phase 2 | |
| Not yet recruiting |
NCT03112057 -
Visualize Nociceptor Changes in Neuropathic Human
|
N/A | |
| Completed |
NCT04262778 -
Diagnostic of Chemotherapy Induced Neuropathy in Children
|
||
| Recruiting |
NCT06324344 -
Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)
|
N/A |